BNT162b2 COVID-19 and ChAdOx1 nCoV-19 vaccination in patients with myelodysplastic syndromes

Haematologica. 2022 May 1;107(5):1181-1184. doi: 10.3324/haematol.2021.280337.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • BNT162 Vaccine
  • COVID-19* / prevention & control
  • ChAdOx1 nCoV-19
  • Humans
  • Myelodysplastic Syndromes* / therapy
  • Vaccination

Substances

  • ChAdOx1 nCoV-19
  • BNT162 Vaccine